This research was carried out To judge the likely of your CPPs with tumor-concentrating on Qualities to deliver a cytotoxic payload to HCC cells. We explored utilizing a CXCR4-targeting peptide, T22, fused with cytotoxic peptide PE24, to be a novel therapeutic method for CXCR4+ HCC cells. T22 was decided on because the nanocarrier as a result of it